Facebook
X
LinkedIn
ForwardDate & Time of Session - 10/1/25 - from 2:30 - 3:30PM
Overview
Throughout the last decade, the advancement of novel immunotherapeutic agents, particularly monoclonal antibodies, have transformed the treatment of pediatric hematologic and solid malignancies1. While initially developed and studied for their decreased side effect profile in comparison to conventional chemotherapy, these agents have since demonstrated significant efficacy in improving response rates and further outcomes1. In pediatric acute lymphoblastic leukemia (ALL), the bispecific T cell-engaging (BiTE) blinatumomab has shown efficacy in relapsed or refractory cases while dinutuximab, an anti-GD2 monoclonal antibody, has shown improvements in overall survival in pediatric neuroblastoma1, 2, 3, 4 . Due to their promising efficacies, the use of these agents has been expanded in further malignancies and stages of disease in combination with other targeted therapies2, 4. The primary objective of this presentation is to evaluate current literature regarding the expanded use of immunotherapy in pediatric malignancies and develop evidence-based recommendations regarding their expanded use.
Objectives
Upon completion of this activity, the participant will be able to:
1. Define key immunotherapy concepts relevant to pediatric oncology
2. Discuss the integration of immunotherapy into current pediatric oncology treatment protocols
3. Analyze current clinical data supporting the use of immunotherapy in hematologic and solid malignancies
Target Audience
Pharmacists, physicians, nurses, fellows and residents
Speaker
Collin Strickland, PharmD, MBA
PGY2 Oncology Pharmacy Resident
Norton Children’s Hospital
Louisville, Kentucky
- 1.00 ACPE
In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.
This knowledge-based activity will award 1.00 contact hour(s) (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.
- 1.00 AMA PRA Category 1 Credit™
In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.
This Live activity is designated for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
- 1.00 ANCC (UK Healthcare CECentral)
In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.00 nursing contact hour(s).
- 1.00 IPCE
In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.
- 1.00 ParticipationUK Healthcare CECentral certifies this activity for 1.00 hour(s) of participation.